Xpovio (Selinexor) Patent Expiration, LOE Window & CMS Spending
Xpovio (Selinexor) by Karyopharm Therapeutics: FDA Orange Book core substance LOE 2035-08-14, 0 AB generics, $105.2M 2024 CMS Part D & Medicaid spend, and 35 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Karyopharm Therapeutics |
| FDA Application & Pathway | N212306 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2035-08-14 |
| Last Listed Patent or Exclusivity Date | 2035-08-14 |
| Orange Book Patents (*PED Extensions) | 11 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $105.2M |
| 2024 Medicare Part D Spend | $98.2M |
| 2024 Medicaid Spend | $7.0M |
| Reported Wholesale Price Change (CA SB 17) | 35 WAC filings (max 32.9% 2-yr change) |